These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12641862)

  • 1. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
    O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
    Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Bellantonio S; Rose DN
    Ann Intern Med; 2003 Sep; 139(5 Pt 1):321-9. PubMed ID: 12965940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
    Shen K; Xiong T; Tan SC; Wu J
    PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of newer treatment strategies for influenza.
    Smith KJ; Roberts MS
    Am J Med; 2002 Sep; 113(4):300-7. PubMed ID: 12361816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.
    Vindt Holm M; Gyldmark M; Holme Hansen E
    Pharm World Sci; 2004 Dec; 26(6):339-45. PubMed ID: 15683104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
    Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
    J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
    Sander B; Hayden FG; Gyldmark M; Garrison LP
    Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
    Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
    Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
    Talbird SE; Brogan AJ; Winiarski AP; Sander B
    Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
    Lee PY; Matchar DB; Clements DA; Huber J; Hamilton JD; Peterson ED
    Ann Intern Med; 2002 Aug; 137(4):225-31. PubMed ID: 12186512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
    Talbird SE; Brogan AJ; Winiarski AP
    Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
    Postma MJ; Beardsworth P; Wilschut JC
    J Med Econ; 2008; 11(4):743-68. PubMed ID: 19450079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of influenza symptoms in healthy adults.
    Rothberg MB; He S; Rose DN
    J Gen Intern Med; 2003 Oct; 18(10):808-15. PubMed ID: 14521643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan.
    Nagase H; Moriwaki K; Kamae M; Yanagisawa S; Kamae I
    Value Health; 2009; 12 Suppl 3():S62-5. PubMed ID: 20586984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness.
    Bruyndonckx R; Bilcke J; van der Velden AW; Li X; Hens N; Coenen S; Butler CC; Beutels P
    Value Health; 2022 Feb; 25(2):178-184. PubMed ID: 35094790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.
    Sander B; Gyldmark M; Hayden FG; Morris J; Mueller E; Bergemann R
    Eur J Health Econ; 2005 Sep; 6(3):244-52. PubMed ID: 15875227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza].
    Li L; Cai B; Wang M; Zhu Y
    Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):838-42. PubMed ID: 16206676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.
    Muennig PA; Khan K
    Clin Infect Dis; 2001 Dec; 33(11):1879-85. PubMed ID: 11692300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.